AU2023232171A1 - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
AU2023232171A1
AU2023232171A1 AU2023232171A AU2023232171A AU2023232171A1 AU 2023232171 A1 AU2023232171 A1 AU 2023232171A1 AU 2023232171 A AU2023232171 A AU 2023232171A AU 2023232171 A AU2023232171 A AU 2023232171A AU 2023232171 A1 AU2023232171 A1 AU 2023232171A1
Authority
AU
Australia
Prior art keywords
inhibitor
checkpoint inhibitor
immune checkpoint
inflammation
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023232171A
Other languages
English (en)
Inventor
Robert E. Davis
Stephen GODING
Gretchen L. Snyder
Maud VOISIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of AU2023232171A1 publication Critical patent/AU2023232171A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2023232171A 2022-03-11 2023-03-11 Organic compounds Pending AU2023232171A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263269209P 2022-03-11 2022-03-11
US63/269,209 2022-03-11
US202363479938P 2023-01-13 2023-01-13
US63/479,938 2023-01-13
PCT/US2023/064202 WO2023173131A2 (en) 2022-03-11 2023-03-11 Organic compounds

Publications (1)

Publication Number Publication Date
AU2023232171A1 true AU2023232171A1 (en) 2024-08-22

Family

ID=87936112

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023232171A Pending AU2023232171A1 (en) 2022-03-11 2023-03-11 Organic compounds

Country Status (8)

Country Link
US (1) US20250186446A1 (cg-RX-API-DMAC10.html)
EP (1) EP4489758A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025509446A (cg-RX-API-DMAC10.html)
KR (1) KR20240158980A (cg-RX-API-DMAC10.html)
AU (1) AU2023232171A1 (cg-RX-API-DMAC10.html)
CA (1) CA3243686A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024010993A (cg-RX-API-DMAC10.html)
WO (1) WO2023173131A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2939676A1 (en) * 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
DK2970279T3 (da) * 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US11291666B2 (en) * 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
CA3047579A1 (en) * 2016-12-22 2018-06-28 Abbvie Inc. Compositions and methods of enhancing or augmenting type i ifn production
JP7493460B2 (ja) * 2018-05-25 2024-05-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020146384A1 (en) * 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) * 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment

Also Published As

Publication number Publication date
MX2024010993A (es) 2024-09-17
KR20240158980A (ko) 2024-11-05
JP2025509446A (ja) 2025-04-11
EP4489758A2 (en) 2025-01-15
CA3243686A1 (en) 2023-09-14
US20250186446A1 (en) 2025-06-12
WO2023173131A2 (en) 2023-09-14
WO2023173131A3 (en) 2023-10-19
EP4489758A4 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
TWI887465B (zh) 用於伊卡洛斯(ikaros)或愛露斯(aiolos)介導之病症之有利療法
US20250186446A1 (en) Organic compounds
JP7856707B2 (ja) 有機化合物
US20240254120A1 (en) Ep4 inhibitors and synthesis thereof
US12599603B2 (en) Methods of treatment
JP7246309B2 (ja) 免疫応答を調節するためのオキサビシクロヘプタン
US20180353602A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
CN118678958A (zh) 药物组合物及其用途
US20230405118A1 (en) Stat-activated macrophages, compositions, and uses thereof
JP7493460B2 (ja) 有機化合物
CN118922191A (zh) 有机化合物
RU2822394C1 (ru) Способы лечения
HK40112650A (en) Organic compounds
HK40066948A (en) Methods of treatment
US20250375458A1 (en) Compositions and methods to combat multidrug-resistant and persistent t-cell-mediated, oncological and infectious diseases
WO2023196988A9 (en) Methods of use of mrnas encoding il-12
HK40113151A (en) Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility
CN118234496A (zh) 检查点抑制剂耐药或耐药易感性的晚期/转移性癌症的改善治疗
BR112017016902B1 (pt) Composição farmacêutica, respectivo uso e uso de plinabulina